IN SILICO HEAD-TO-HEAD COMPARISON OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC IN TYPE 1 DIABETES

被引：0
|
作者：
Visentin, R. [1 ]
Schiavon, M. [1 ]
Giegerich, C. [2 ]
Sieber, J. [2 ]
Man, C. Dalla [1 ]
Cobelli, C. [1 ]
Klabunde, T. [2 ]
机构：
[1] Univ Padua, Dept Informat Engn, Padua, Italy
[2] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
037
引用
收藏
页码：A18 / A18
页数：1
相关论文
共 50 条
  • [1] In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
    Schiavon, Michele
    Visentin, Roberto
    Giegerich, Clemens
    Sieber, Jochen
    Dalla Man, Chiara
    Cobelli, Claudio
    Klabunde, Thomas
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (08) : 553 - 561
  • [2] A PK/PD and Metabolic Head-to-Head Comparison of Clinical Doses of Insulin Glargine U300 and Degludec in Type 1 Diabetes
    Lucidi, Paola
    Porcellati, Francesca
    Candeloro, Paola
    Cioli, Patrizia
    Pascucci, Chiara
    Bolli, Geremia B.
    Fanelli, Carmine
    DIABETES, 2019, 68
  • [3] Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units . mL-1 and Insulin Degludec 100 units . mL-1 in Type 1 Diabetes
    Lucidi, Paola
    Candeloro, Paola
    Cioli, Patrizia
    Marinelli Andreoli, Anna
    Pascucci, Chiara
    Gambelunghe, Angela
    Bolli, Geremia B.
    Fanelli, Carmine G.
    Porcellati, Francesca
    DIABETES CARE, 2021, 44 (01) : 125 - 132
  • [4] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
    Philis-Tsimikas, Athena
    Klonoff, David C.
    Khunti, Kamlesh
    Bajaj, Harpreet S.
    Leiter, Lawrence A.
    Hansen, Melissa, V
    Troelsen, Lone N.
    Ladelund, Steen
    Heller, Simon
    Pieber, Thomas R.
    DIABETOLOGIA, 2020, 63 (04) : 698 - 710
  • [5] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
    Athena Philis-Tsimikas
    David C. Klonoff
    Kamlesh Khunti
    Harpreet S. Bajaj
    Lawrence A. Leiter
    Melissa V. Hansen
    Lone N. Troelsen
    Steen Ladelund
    Simon Heller
    Thomas R. Pieber
    Diabetologia, 2020, 63 : 698 - 710
  • [6] More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
    Rosenstock, Julio
    Cheng, Alice
    Ritzel, Robert
    Bosnyak, Zsolt
    Devisme, Christine
    Cali, Anna M. G.
    Sieber, Jochen
    Stella, Peter
    Wang, Xiangling
    Frias, Juan P.
    Roussel, Ronan
    Bolli, Geremia B.
    DIABETES CARE, 2018, 41 (10) : 2147 - 2154
  • [7] Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats
    Gilor, C.
    Culp, W.
    Ghandi, S.
    do Carmo Emidio e Silva, J. A.
    Ladhar, A.
    Hulsebosch, S.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2019, 69 : 19 - 29
  • [8] EFFICACY AND SAFETY OF INSULIN GLARGINE-300 U/ML VS INSULIN DEGLUDEC-100 U/ML IN INSULIN-NAIVE ADULTS WITH T2DM: FIRST HEAD-TO-HEAD RANDOMISED CLINICAL TRIAL
    Cheng, A.
    Rosenstock, J.
    Ritzel, R.
    Bosnyak, Z.
    Devisme, C.
    Wang, X.
    Sieber, J.
    Roussel, R.
    Bolli, G. B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A30
  • [9] Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial
    Battelino, Tadej
    Danne, Thomas
    Edelman, Steve, V
    Choudhary, Pratik
    Renard, Eric
    Westerbacka, Jukka
    Mukherjee, Bhaswati
    Pilorget, Valerie
    Coudert, Mathieu
    Bergenstal, Richard M.
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 545 - 555
  • [10] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SLOVENIA
    Bogdanovic, M.
    Krnel, Rados S.
    Foumier, M.
    VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
12345